These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27802183)

  • 1. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
    Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
    Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
    Shoji H; Yamada Y; Okita N; Takashima A; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Anticancer Res; 2015 Sep; 35(9):5055-61. PubMed ID: 26254407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.
    Hur JY; Chao J; Kim K; Kim ST; Kim KM; Klempner SJ; Lee J
    Pathol Res Pract; 2020 Apr; 216(4):152878. PubMed ID: 32089408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.
    Jung EJ; Jung EJ; Min SY; Kim MA; Kim WH
    Hum Pathol; 2012 Oct; 43(10):1559-66. PubMed ID: 22440694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
    Sclafani F; Morano F; Cunningham D; Baratelli C; Kalaitzaki E; Watkins D; Starling N; Chau I; Rao S
    Oncologist; 2017 Apr; 22(4):402-408. PubMed ID: 28209745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
    Ahn S; Lee J; Hong M; Kim ST; Park SH; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Jung SH; Kang WK; Kim KM
    Mod Pathol; 2016 Sep; 29(9):1095-103. PubMed ID: 27230412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR2 gene amplification and clinicopathological features in gastric cancer.
    Matsumoto K; Arao T; Hamaguchi T; Shimada Y; Kato K; Oda I; Taniguchi H; Koizumi F; Yanagihara K; Sasaki H; Nishio K; Yamada Y
    Br J Cancer; 2012 Feb; 106(4):727-32. PubMed ID: 22240789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.
    Wu X; Zhou F; Ji X; Ren K; Shan Y; Mao X; Fen Y; Chen R; Ding H; Fu X
    Future Oncol; 2017 Dec; 13(29):2691-2696. PubMed ID: 28972404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA Analysis Detects
    Jogo T; Nakamura Y; Shitara K; Bando H; Yasui H; Esaki T; Terazawa T; Satoh T; Shinozaki E; Nishina T; Sunakawa Y; Komatsu Y; Hara H; Oki E; Matsuhashi N; Ohta T; Kato T; Ohtsubo K; Kawakami T; Okano N; Yamamoto Y; Yamada T; Tsuji A; Odegaard JI; Taniguchi H; Doi T; Fujii S; Yoshino T
    Clin Cancer Res; 2021 Oct; 27(20):5619-5627. PubMed ID: 34376535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
    Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
    Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
    Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
    Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
    Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
    Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
    Van Cutsem E; Bang YJ; Mansoor W; Petty RD; Chao Y; Cunningham D; Ferry DR; Smith NR; Frewer P; Ratnayake J; Stockman PK; Kilgour E; Landers D
    Ann Oncol; 2017 Jun; 28(6):1316-1324. PubMed ID: 29177434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative nodal status and diffuse-type histology are independent prognostic factors in resectable advanced gastric carcinomas after preoperative chemotherapy.
    Koh YW; Park YS; Ryu MH; Ryoo BY; Park HJ; Yook JH; Kim BS; Kang YK
    Am J Surg Pathol; 2013 Jul; 37(7):1022-9. PubMed ID: 23715160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relationship Between ZEB1-AS1 Expression and the Prognosis of Patients With Advanced Gastric Cancer Receiving Chemotherapy.
    Chai H; Sun C; Liu J; Sheng H; Zhao R; Feng Z
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819849069. PubMed ID: 31072267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
    Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
    Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.